Literature DB >> 23697558

Interleukin-8 in breast cancer progression.

Nataša Todorović-Raković1, Jelena Milovanović.   

Abstract

Interleukin-8 (IL-8) is a chemokine that has an autocrine and/or paracrine tumor-promoting role and significant potential as a prognostic and/or predictive cancer biomarker. In breast cancer, which is mostly determined by expression of estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2), IL-8 could play a specific role. IL-8 is highly expressed in ER- breast cancers, but it increases invasiveness and metastatic potential of both ER- and ER+ breast cancer cells. It is also highly expressed in HER2+ breast cancers. Because of the complex crosstalk between these receptors and IL-8, its role is mainly determined by delicate balance in their signaling pathways. Therefore, the main point of this review was to analyze the possible influence of IL-8 in breast cancer progression related to its interaction with ER and HER2 and the consequent therapeutic implications of these relations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23697558      PMCID: PMC3793647          DOI: 10.1089/jir.2013.0023

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  74 in total

1.  Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.

Authors:  Alejandro Vazquez-Martin; Ramon Colomer; Javier A Menendez
Journal:  Eur J Cancer       Date:  2007-03-26       Impact factor: 9.162

2.  Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis.

Authors:  Aihua Li; Michelle L Varney; Jason Valasek; Maurice Godfrey; Bhavana J Dave; Rakesh K Singh
Journal:  Angiogenesis       Date:  2005       Impact factor: 9.596

3.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Authors:  Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

4.  Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy.

Authors:  Dina Chelouche-Lev; Claudia P Miller; Carmen Tellez; Maribelis Ruiz; Menashe Bar-Eli; Janet E Price
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

Review 5.  Steroid hormone receptors in breast cancer management.

Authors:  C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

6.  Structure and functional expression of a human interleukin-8 receptor.

Authors:  W E Holmes; J Lee; W J Kuang; G C Rice; W I Wood
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

7.  Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer.

Authors:  Jie Yang; Yue Wang; Yan Gao; Jie Shao; Xue Jun Zhang; Zhi Yao
Journal:  Cytokine       Date:  2009-04-28       Impact factor: 3.861

8.  Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.

Authors:  Vummidi Giridhar Premkumar; Srinivasan Yuvaraj; Kothandaraman Vijayasarathy; Sitthu Govindaswamy Dinakaran Gangadaran; Panchanatham Sachdanandam
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-06       Impact factor: 4.080

Review 9.  Acquired endocrine resistance in breast cancer: implications for tumour metastasis.

Authors:  Edd Hayes; Robert I Nicholson; Stephen Hiscox
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

Review 10.  Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.

Authors:  Pierre-Emmanuel Colombo; Fernanda Milanezi; Britta Weigelt; Jorge S Reis-Filho
Journal:  Breast Cancer Res       Date:  2011-06-27       Impact factor: 6.466

View more
  60 in total

1.  Senescent Breast Luminal Cells Promote Carcinogenesis through Interleukin-8-Dependent Activation of Stromal Fibroblasts.

Authors:  Huda H Al-Khalaf; Hazem Ghebeh; Rabia Inass; Abdelilah Aboussekhra
Journal:  Mol Cell Biol       Date:  2019-01-03       Impact factor: 4.272

2.  Interleukin 8 in progression of hormone-dependent early breast cancer.

Authors:  Jelena Milovanovic; Natasa Todorovic-Rakovic; Tijana Vujasinovic; Zaki Abu Rabi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

3.  IL-8 induces the epithelial-mesenchymal transition of renal cell carcinoma cells through the activation of AKT signaling.

Authors:  Nan Zhou; Fuding Lu; Cheng Liu; Kewei Xu; Jian Huang; Dexin Yu; Liangkuan Bi
Journal:  Oncol Lett       Date:  2016-07-21       Impact factor: 2.967

Review 4.  Harnessing the immune system for the treatment of breast cancer.

Authors:  Xinguo Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

5.  Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway.

Authors:  Ran Xu; Chao Shang; Jungang Zhao; Yun Han; Jun Liu; Kuanbing Chen; Wenjun Shi
Journal:  Tumour Biol       Date:  2015-05-12

6.  Temporal trends in the inflammatory cytokine profile of human breastmilk.

Authors:  Lynn S Chollet-Hinton; Alison M Stuebe; Patricia Casbas-Hernandez; Ellen Chetwynd; Melissa A Troester
Journal:  Breastfeed Med       Date:  2014-12       Impact factor: 1.817

7.  Differences in tumor stroma derived from irradiated versus non-irradiated fibroblasts in a co-culture model with head and neck squamous cell carcinoma.

Authors:  Thomas Gehrke; Agmal Scherzad; Stephan Hackenberg; Philipp Schendzielorz; Rudolf Hagen; Norbert Kleinsasser
Journal:  Oncol Lett       Date:  2016-09-01       Impact factor: 2.967

Review 8.  Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy.

Authors:  Sachin Kumar Deshmukh; Sanjeev Kumar Srivastava; Teja Poosarla; Donna Lynn Dyess; Nicolette Paolaungthong Holliday; Ajay Pratap Singh; Seema Singh
Journal:  Ann Transl Med       Date:  2019-10

9.  Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS).

Authors:  Frank He; Nora L Springer; Matthew A Whitman; Siddharth P Pathi; Yeonkyung Lee; Sunish Mohanan; Stephen Marcott; Aaron E Chiou; Bryant S Blank; Neil Iyengar; Patrick G Morris; Maxine Jochelson; Clifford A Hudis; Pragya Shah; Jennie A M R Kunitake; Lara A Estroff; Jan Lammerding; Claudia Fischbach
Journal:  Biomaterials       Date:  2019-09-11       Impact factor: 12.479

10.  Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown.

Authors:  Su-Hyeong Kim; Eun-Ryeong Hahm; Julie A Arlotti; Suman K Samanta; Michelle B Moura; Stephen H Thorne; Yongli Shuai; Carolyn J Anderson; Alexander G White; Anna Lokshin; Joomin Lee; Shivendra V Singh
Journal:  Breast Cancer Res Treat       Date:  2016-04-21       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.